Pay in 4 interest-free payments of $6.83 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
61 ECC5004 The preliminary results of the investigational agent ECC5004 phase 1 trial in non-human primates revealed a reduction in HbA1c levels, accompanied by weight loss and a decreased risk of adverse cardiovascular events, achieved through the mimicry of the hormone GLP-1
Summary and future directions The ability of GHK and its Cu chelate to promote skin remodeling, wound healing and regeneration, and its prominent antioxidant and anti-inflammatory effects are qualities that will help enhance healthy aging [28-31]
Phase 3 results showed approximately 15-17% body weight reduction over 48 weeks, positioning it competitively with tirzepatide
Unless you have specific reasons to try alternatives, GHK-Cu remains the standard
US$ 21.24
US$ 20.12
US$ 27.56
US$ 26.35
US$ 29.29
US$ 22.89
US$ 22.41
